NecstGen announces the addition of Johan Hyllner to its strategic advisory board. Johan Hyllner is leading expert in cell therapy and enabling technologies. He is professor of engineering biology at Linköping University, Sweden and head of the Cell...

NecstGen announces that the Dutch constructor Kuijpers has obtained the contract for the construction of its Cell- and Gene Therapy facility. Throughout the next year, NecstGen’s facility will be constructed in Mirai House on the largest Life Science...

Today, Meindert Stolk, deputy Economy and Innovation of the Province South Holland visited NecstGen to hand over a symbolic cheque of € 2 million to Paul Bilars, CEO of NecstGen. Throughout the last years, the province has been closely involved with...

Today, the Dutch cabinet announced the investment of €56 million into the establishment of a “pilot factory” for regenerative therapies. NecstGen and three other facilities will form a chain covering the...

NECSTGEN announces the addition of Markwin Velders to its strategic advisory board. Markwin Velders brings almost 20 years of experience as entrepreneur in the field of cell and gene therapy. He is Chairman of HollandBIO and co-founder of various...

NECSTGEN announces the appointment of Sander van Deventer to its strategic advisory board. Sander van Deventer adds both scientific as well as commercial expertise in the field of cell and gene therapy. He is professor of Translational gastroenterology...

NECSTGEN has started a collaboration with IT-partner LINKIT. NECSTGEN is a spin out of the Leiden University Medical Center that will support clinicians, academic groups and small industrial therapy developers globally to bring cell and gene therapies...

We are happy to announce the official launch of the Netherlands Center for the Clinical Advancement of Stem Cell & Gene Therapies (NECSTGEN). The new center has been established to accelerate the development and clinical realization of cell and...

A collaboration between Regenerative Medicine Crossing Borders (RegMed XB) and the Dutch CardioVascular Alliance (DCVA) will receive an investment of 8 million euros from the Dutch government to set up a new valorisation platform. This facilitates...